We serve cardiac and vascular nurses, technologists, educators, managers, and directors. In a field that is continually evolving, CathLab.com is the industry professional’s #1 resource for product insights, news, education and job opportunities.
Find a Job
The phase III VICTORIA trial of vericiguat, an investigational drug for patients worsening chronic heart failure and reduced ejection fraction, met its primary endpoint, drugmakers Merck and Bayer AG announced on Monday.
LONDON, England—Follow-up data from the PORTICO I study testing the self-expanding Portico transcatheter heart valve (Abbott) show a low rate of cardiovascular mortality and disabling stroke at 2 years, as well as continued low transvalvular gradients and large valve areas.
Summarizing the Educational Symposium
Simplifying complex PCI guided by a 2nd generation fiber-optic physiology guidewire.
Stay Up-To-Date on jobs and industry news.
Sign up for the CathLab.com newsletter today!